

Third good quarter in a row — Outlook confirmed

November 4, 2016

- Volume growth continued in the third quarter
- Adjusted EBITDA margin at a very good level of 18.1 percent in the first nine months
- Financing of the planned acquisition of Air Products' specialty and coating additives business secured at an average interest rate of 0.35 percent
- Outlook for FY 2016 confirmed

Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
tim.lange@evonik.com

Essen. "In the third quarter of 2016 Evonik continued the volume growth seen in the first six months, despite the weak global economic conditions," reported Klaus Engel, Chairman of the Executive Board of Evonik Industries. "Based on this, we are confirming our outlook for the full year."

In the first nine months of this year, **Group sales** declined 8 percent year-on-year to €9,527 million. This was mainly due to lower selling prices. At the same time, volume sales rose by 2 percent. **Adjusted EBITDA** was 12 percent below the very high prior-year level at €1,728 million. The **adjusted EBITDA margin** was very good at 18.1 percent.

Adjusted EBIT shrank by 18 percent to €1,191 million. **Adjusted net income** declined 19 percent to €501 million. **Net income** was €628 million, down 27 percent from the high prior-year level, which contained the proceeds from the divestment of the stake in Vivawest.

Evonik generated a clearly positive **free cash flow** of €488 million in the first nine months of 2016. This was partly due to a reduction in net working capital, while **capital expenditures** for property, plant and equipment were around the prior-year level at €589 million.

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann, Deputy Chairman
Dr. Ralph Sven Kaufmann
Thomas Wessel
Ute Wolf

Outlook

Evonik still expects sales for the full year to be slightly below the €13.5 billion reported in the previous year. Thanks to its strong market positions, balanced portfolio and concentration on high-growth businesses, the company assumes there will be continued high demand for its products and appreciable volume growth despite the difficult macro-economic conditions. The new production capacities taken into service in recent years and further intensification of sales activities are contributing to this. Selling prices are declining considerably, especially in the Nutrition & Care and Performance Materials segments, leading to the forecast slight reduction in sales.

Evonik is confirming the outlook for adjusted EBITDA specified at the end of the first six months: The company is confident that it can realize adjusted EBITDA in the upper half of the anticipated range of €2.0 billion to €2.2 billion.

Performance in Q3

The positive volume trend continued in the third quarter of 2016, with good demand for Evonik's products worldwide. Selling prices declined further, partly because lower raw material prices were passed on to customers. The Group posted a drop of 6 percent in sales to €3,164 million. **Adjusted EBITDA** was €578 million, 11 percent lower than in the exceptionally strong prior-year quarter. The **adjusted EBITDA margin** was very good at 18.3 percent. **Adjusted EBIT** declined 16 percent to €396 million. **Adjusted net income** declined 17 percent to €247 million. **Net income** increased 19 percent to €223 million as a result of the reduced impact of one-off factors.

Acquisition of Air Products' Performance Materials Division

In September 2016 Evonik successfully placed bonds with a nominal value of €1.9 billion and an average interest rate of 0.35 percent on the capital market via its subsidiary Evonik Finance B.V. The proceeds will be used to finance the planned acquisition of Air Products' specialty and coating additives

business. The responsible antitrust authorities in the USA, Germany and most European countries have already approved the transaction, which is expected to be closed by the end of the year.

Details of segment performance

In the **Nutrition & Care** segment sales declined 14 percent to €1,066 million in the **third quarter** of 2016. Since volumes were stable compared with the strong prior-year period, this was mainly attributable to lower selling prices. Adjusted EBITDA was €239 million, which was below the very high prior-year level of €382 million, mainly on price grounds. The adjusted EBITDA margin dropped to 22.4 percent. In the **first nine months of 2016** sales in the Nutrition & Care segment fell by 13 percent to €3,223 million. Since volumes were virtually unchanged, the decline was attributable to considerably lower selling prices. Adjusted EBITDA was 29 percent below the very strong prior-year level at €796 million. The adjusted EBITDA margin remains very good at 24.7 percent.

The **Resource Efficiency** segment continued its successful business performance in the **third quarter of 2016**. Sales rose 7 percent to €1,117 million, driven principally by clear volume growth. Selling prices slipped slightly, mainly because lower raw material costs were passed on to customers. Adjusted EBITDA improved 21 percent to €262 million, mainly as a consequence of higher volumes and favorable raw material costs. The adjusted EBITDA margin improved to a very good 23.5 percent. In the **first nine months** of the year, sales in the Resource Efficiency segment increased 3 percent to €3,392 million. This was mainly due to higher volumes, while the reduction in selling prices driven by raw material prices had a counter-effect. **Adjusted EBITDA** rose by 10 percent to €788 million. The adjusted EBITDA margin improved from 21.8 percent to a very good level of 23.2 percent.

In the **Performance Materials** segment, sales dropped 7 percent to €797 million in the **third quarter of 2016**. The main reason was the reduction in selling prices as lower raw material costs were passed on to customers. By contrast, volumes rose considerably thanks to good demand. Adjusted EBITDA grew 11 percent to

€104 million. This was primarily due to a rise in volumes, high capacity utilization at production facilities, and the initial effects of cost-cutting measures. The adjusted EBITDA margin was 13.0 percent, up from 11.0 percent in the third quarter of 2015. In the **first nine months** of the year, sales in the Performance Materials segment shrank 9 percent to €2,399 million. With volumes up, the decline was caused by the oil-driven drop in selling prices. Adjusted EBITDA improved 11 percent to €273 million and the adjusted EBITDA margin rose to 11.4 percent.

Evonik Group: Excerpt from the income statement

(in € million)	Q3 2016	Q3 2015	Change in %	9M 2016	9M 2015	Change in %
Sales	3,164	3,365	-6	9,527	10,309	-8
Adjusted EBITDA	578	653	-11	1,728	1,964	-12
Adjusted EBIT	396	473	-16	1,191	1,444	-18
Adjustments	-15	-91		-74	-6	
Financial result	-55	-86		-183	-200	
Income before income taxes, continuing operations	326	296	10	934	1,238	-25
Income taxes	-100	-105		-297	-354	
Income after taxes, continuing operations	226	191	18	637	884	-28
Income after taxes, discontinued operations	1	-		1	-15	
Income after taxes	227	191	19	638	869	-27
thereof attributable to non-controlling interests	4	3		10	7	
Net income	223	188	19	628	862	-27
Adjusted net income	247	296	-17	748	923	-19

Prior-year figures restated

Segment performance

	Sales Q3			Adjusted EBITDA Q3		
	2016 € million	2015 € million	Change in %	2016 € million	2015 € million	Change in %
Nutrition & Care	1,066	1,240	-14	239	382	-37
Resource Efficiency	1,117	1,044	7	262	216	21
Performance Materials	797	858	-7	104	94	11
Services	173	207	-16	50	46	9
Other operations	11	16		-21	-34	
Group	3,164	3,365	-6	578	653	-11
	Sales 9M			Adjusted EBITDA 9M		
	2016 € million	2015 € million	Change in %	2016 € million	2015 € million	Change in %
Nutrition & Care	3,223	3,716	-13	796	1,116	-29
Resource Efficiency	3,392	3,278	3	788	714	10
Performance Materials	2,399	2,646	-9	273	247	11
Services	503	626	-20	119	119	-
Other operations	10	54		-80	-79	
Group	9,527	10,309	-8	1,728	1,964	-12

Prior-year figures restated

Employees by segment

	Sept. 30, 2016	Dec. 31, 2015
Nutrition & Care	7,550	7,165
Resource Efficiency	8,879	8,662
Performance Materials	4,421	4,380
Services	12,896	12,668
Other operations	531	701
Evonik	34,277	33,576

Prior-year figures restated

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.